BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15509160)

  • 1. Toward a pharmacophore for kinase frequent hitters.
    Aronov AM; Murcko MA
    J Med Chem; 2004 Nov; 47(23):5616-9. PubMed ID: 15509160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
    Aronov AM; McClain B; Moody CS; Murcko MA
    J Med Chem; 2008 Mar; 51(5):1214-22. PubMed ID: 18288794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacophore map of small molecule protein kinase inhibitors.
    McGregor MJ
    J Chem Inf Model; 2007; 47(6):2374-82. PubMed ID: 17941626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H; Wang Z; Zhang L; Zhang J; Huang Q
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium half-sandwich complexes as protein kinase inhibitors: derivatization of the pyridocarbazole pharmacophore ligand.
    Pagano N; Maksimoska J; Bregman H; Williams DS; Webster RD; Xue F; Meggers E
    Org Biomol Chem; 2007 Apr; 5(8):1218-27. PubMed ID: 17406720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S; Stanton RV; Johnson TL; Xi H
    Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of structure in kinase-targeted inhibitor design.
    Pratt DJ; Endicott JA; Noble ME
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):428-36. PubMed ID: 15338952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
    Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
    J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CORES: an automated method for generating three-dimensional models of protein/ligand complexes.
    Hare BJ; Walters WP; Caron PR; Bemis GW
    J Med Chem; 2004 Sep; 47(19):4731-40. PubMed ID: 15341488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finding protein kinase hits using structural information.
    Cherry M; Reader J; Williams D
    Prog Med Chem; 2006; 44():1-63. PubMed ID: 16697894
    [No Abstract]   [Full Text] [Related]  

  • 11. Selectivity assessment of kinase inhibitors: strategies and challenges.
    Luo Y
    Curr Opin Mol Ther; 2005 Jun; 7(3):251-5. PubMed ID: 15977423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors.
    Wichapong K; Lindner M; Pianwanit S; Kokpol S; Sippl W
    Eur J Med Chem; 2009 Apr; 44(4):1383-95. PubMed ID: 18976834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction profiles of protein kinase-inhibitor complexes and their application to virtual screening.
    Chuaqui C; Deng Z; Singh J
    J Med Chem; 2005 Jan; 48(1):121-33. PubMed ID: 15634006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
    Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
    J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.
    Simard JR; Getlik M; Grütter C; Schneider R; Wulfert S; Rauh D
    J Am Chem Soc; 2010 Mar; 132(12):4152-60. PubMed ID: 20201574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D QSAR studies on a series of potent and high selective inhibitors for three kinases of RTK family.
    Cao H; Zhang H; Zheng X; Gao D
    J Mol Graph Model; 2007 Jul; 26(1):236-45. PubMed ID: 17293140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    Sheinerman FB; Giraud E; Laoui A
    J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taming the induced folding of drug-targeted kinases.
    Fernández A; Bazán S; Chen J
    Trends Pharmacol Sci; 2009 Feb; 30(2):66-71. PubMed ID: 19097649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes.
    Singh J; Deng Z; Narale G; Chuaqui C
    Chem Biol Drug Des; 2006 Jan; 67(1):5-12. PubMed ID: 16492144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors.
    Laufer SA; Domeyer DM; Scior TR; Albrecht W; Hauser DR
    J Med Chem; 2005 Feb; 48(3):710-22. PubMed ID: 15689155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.